Caris Life Sciences Gains MolDX Approval for ChromoSeq
IRVING, Texas – May 4, 2026 Caris Life Sciences has secured MolDX approval for its flagship Caris ChromoSeq™ assay,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
IRVING, Texas – May 4, 2026 Caris Life Sciences has secured MolDX approval for its flagship Caris ChromoSeq™ assay,...
BRISBANE, Calif., Feb. 12, 2026 — CareDx announced pivotal clinical validation results for AlloHeme, the first AI-powered, next-generation sequencing...
